Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)


Avidity Biosciences

Status and phase

Phase 2
Phase 1


Muscular Dystrophy, Landouzy Dejerine
Fascioscapulohumeral Muscular Dystrophy
Fascioscapulohumeral Muscular Dystrophy Type 1
FSH Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy 2
Fascioscapulohumeral Muscular Dystrophy Type 2
Atrophy, Facioscapulohumeral
Muscular Dystrophy, Facioscapulohumeral
Atrophies, Facioscapulohumeral
Progressive Muscular Dystrophy
Landouzy-Dejerine Muscular Dystrophy
Facio-Scapulo-Humeral Dystrophy
Facioscapulohumeral Muscular Dystrophy 1
Dystrophies, Facioscapulohumeral Muscular
Facioscapulohumeral Atrophy
Dystrophy, Landouzy-Dejerine
Dystrophies, Landouzy-Dejerine
Landouzy Dejerine Dystrophy
Muscular Dystrophies
Dystrophy, Facioscapulohumeral Muscular
Landouzy-Dejerine Syndrome


Drug: AOC 1020
Drug: Placebo

Study type


Funder types



2022-502096-32-00 (Other Identifier)
2022-002704-20 (EudraCT Number)
AOC 1020-CS1

Details and patient eligibility


A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Full description

AOC 1020-CS1 is a first-in-human, 3-part, multi-center, Phase 1/2, randomized, double-blind, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics and to explore pharmacodynamics and efficacy of single and multiple-doses of AOC 1020 administered intravenously in adult participants with FSHD Type 1 (FSHD1) and FSHD Type 2 (FSHD2). Part A is a dose titration design which includes a single and multiple dose schedule with 1 cohort. Part B is a single-ascending and multiple-ascending dose design with 2 cohorts. Part C is a parallel, multi-dose cohort design with 1 cohort. For each of Part A, B, and C the patient duration is 12 months as the active treatment period is approximately 9 months followed by a 3-month follow-up period. Once participants have completed active treatment and the follow-up period, they may have the option to participate in a planned open-label extension. If patients do not enroll in the open-label extension, they will be followed through a 6-month safety follow-up period.


72 estimated patients




18 to 65 years old


No Healthy Volunteers

Inclusion criteria

  • FSHD1 or FSHD2 diagnosis confirmed by documented genetic testing (testing provided by Sponsor)
  • Ambulatory and able to walk 10 meters (with or without assistive devices such as one cane, walking stick or braces)
  • At least 1 muscle region suitable for biopsy (testing provided by Sponsor)
  • Muscle weakness in both upper and lower body, as determined by Investigator

Exclusion criteria

  • Pregnancy, intent to become pregnant within 9 months after last planned dose of Study Drug, or active breastfeeding
  • Unwilling or unable to continue to comply with contraceptive requirements
  • Body mass index (BMI) >35.0 kg/m2 at Screening
  • History of muscle biopsy within 30 days of the screening biopsy or planning to undergo any nonstudy muscle biopsies over the duration of the study
  • History of bleeding disorders, significant keloid, or other skin or muscle conditions (e.g., severe muscle wasting) that, in the opinion of the Investigator, makes the participant unsuitable for serial muscle biopsy
  • Anticipated survival less than 2 years
  • Blood or plasma donation within 16 weeks of Study Day 1
  • Any contraindication to MRI
  • Any abnormal lab values, conditions or diseases that, in the opinion of the investigator or Sponsor, would make the participant unsuitable for the study or could interfere with participation or completion of the study
  • Treatment with any investigative medication within 1 month (or 5 half-lives of the drug, whichever is longer) of Screening

Trial design

72 participants in 4 patient groups, including a placebo group

AOC 1020 Regimen 1
Experimental group
Part A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months
Drug: AOC 1020
AOC 1020 Regimen 2
Experimental group
Part B1 & C: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months
Drug: AOC 1020
AOC 1020 Regimen 3
Experimental group
Part B2 & C: AOC 1020 Dose Regimen 3; Five doses administered intravenously over 9 months
Drug: AOC 1020
Placebo (Saline)
Placebo Comparator group
Part A, B & C: Placebo; Five doses administered intravenously over 9 months
Drug: Placebo

Trial contacts and locations



Central trial contact

Amy Halseth, PhD

Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems